Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
The EMPA-REG OUTCOME trial results reveal that Jardiance (empagliflozin) significantly reduces the risk of total cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Compared to placebo, Jardiance decreased the relative risk of 3P-MACE by 22%, heart failure hospitalizations by 42%, and all-cause hospitalizations by 17%. These findings underscore the long-term cardiovascular benefits of Jardiance and the ongoing commitment of Boehringer Ingelheim and Eli Lilly to enhance health outcomes in this patient population.
Eli Lilly and Company (NYSE: LLY) is set to participate in the Wolfe Research Virtual Healthcare Conference on November 18, 2020. Joshua Smiley, the company's CFO, will engage in a virtual fireside chat at 1:30 p.m. ET. Investors and interested parties can access a live audio webcast through the Webcasts & Presentations section of Lilly's Investor website, with a replay available for 90 days following the event.
Lilly aims to enhance global healthcare through innovative medicines and community engagement.
Eli Lilly and Company (NYSE: LLY) will join the Bernstein Operational Decisions Conference on November 16, 2020. Key executives, including Andrew Adams and Jeff Emmick, will engage in a virtual fireside chat at 11:00 a.m. ET. A live audio webcast can be accessed via Lilly's Investor website, with a replay available for 90 days. Lilly is committed to advancing healthcare by developing innovative medicines and enhancing disease management. For more details, visit www.lilly.com.
Eli Lilly and Company (NYSE: LLY) will host a webcast on November 20, 2020, at 11:00 a.m. EST, to discuss the Phase 3 clinical trial program for tirzepatide, aimed at treating type 2 diabetes. The session will cover trial designs and the expected schedule for multiple top-line data disclosures. Investors, media, and the public can access the webcast via Lilly's investor website, with a replay available afterwards. The announcement emphasizes Lilly's ongoing commitment to developing effective treatments, while recognizing the uncertainties involved in pharmaceutical research.
The FDA has granted Emergency Use Authorization (EUA) to Eli Lilly's investigational neutralizing antibody, bamlanivimab (LY-CoV555) 700 mg, for treating mild to moderate COVID-19 in patients aged 12 and older who are at high risk of severe illness. Administered via a single intravenous infusion, bamlanivimab is designed to be given within 10 days of symptom onset. This authorization is based on data from the BLAZE-1 clinical trial, which showed significant reduction in viral load and related hospitalizations. The U.S. government has purchased 300,000 doses to ensure accessibility.
Loxo Oncology at Lilly announced the presentation of data on LOXO-305, an investigational BTK inhibitor, at the ASH Annual Meeting from December 5-8, 2020. Updated clinical data from the Phase 1/2 BRUIN trial will be shared, focusing on previously treated chronic lymphocytic leukemia and other non-Hodgkin lymphomas. Presentations will include a Phase 1/2 study's results and pre-clinical evaluations combining LOXO-305 with other therapies. The trial aims to assess LOXO-305's safety, efficacy, and recommended dosages.
Eli Lilly and Company (NYSE: LLY) announced the retirement of Aarti Shah, Ph.D., senior vice president and chief information and digital officer, in the first half of 2021 after 27 years of service. A search for her successor is underway. CEO David A. Ricks praised Shah's contributions, highlighting her leadership in connecting IT with drug development, manufacturing, and commercial capabilities. Shah's tenure included roles in biometrics and brand development. The company acknowledges potential risks related to leadership changes and the challenge of finding her successor.
On November 2, 2020, Eli Lilly and Incyte announced positive long-term data for Olumiant (baricitinib) to be presented at ACR Convergence 2020. Key findings show that 27.5% of csDMARD-IR and 18.4% of bDMARD-IR patients achieved Low Disease Activity after 2.3 years. In a 5-year study, low rates of radiographic progression were maintained across various RA patient populations. No new safety concerns were identified, reinforcing Olumiant's long-term efficacy and safety for moderate to severe rheumatoid arthritis treatments.
Eli Lilly and Incyte announced new data for baricitinib presented at the 29th annual EADV Congress, showcasing its long-term efficacy in treating moderate to severe atopic dermatitis. In the BREEZE-AD3 Phase 3 study, over 40% of patients maintained clear skin after 68 weeks of treatment. Baricitinib received EU approval for adult patients who qualify for systemic therapy. The safety profile aligns with previous studies, reinforcing its potential role in managing this chronic condition ultimately impacting approximately 1-3% of adults worldwide.
Eli Lilly and Incyte presented data for baricitinib at the virtual Fall Clinical Dermatology meeting from Oct 29 to Nov 1, 2020. The Phase 2 study (BRAVE-AA1) evaluated its efficacy in adult patients with alopecia areata (AA). Results showed significant improvement in patients achieving a SALT score ≤20 at 36 weeks, with the 4-mg dose showing 51.9% improvement versus 3.6% for placebo (p=0.001). Following positive Phase 2 results, Phase 3 trials (BRAVE-AA1 and BRAVE-AA2) have been initiated. The FDA has granted Breakthrough Therapy designation for baricitinib for AA due to unmet medical needs.
FAQ
What is the current stock price of Lilly Eli & Co (LLY)?
What is the market cap of Lilly Eli & Co (LLY)?
